Inozyme Pharma to Present at Upcoming Investor Conferences
11 nov. 2024 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
05 nov. 2024 08h30 HE
|
Inozyme Pharma Inc.
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
24 oct. 2024 13h15 HE
|
Inozyme Pharma Inc.
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with...
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
17 oct. 2024 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
07 oct. 2024 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
26 sept. 2024 08h00 HE
|
Inozyme Pharma Inc.
- Data underscore the urgent need for therapies that address the cardiovascular and musculoskeletal complications and long-term systemic effects of ENPP1 and ABCC6 Deficiencies in children - -...
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
29 août 2024 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
06 août 2024 08h30 HE
|
Inozyme Pharma Inc.
Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
25 juil. 2024 08h30 HE
|
Inozyme Pharma Inc.
- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July 25,...
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
02 juil. 2024 08h30 HE
|
Inozyme Pharma Inc.
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...